Commodore Capital’s Karyopharm Therapeutics KPTI Stock Holding History

Commodore Capital’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.9M	Buy	+1,950,000	New	+$14.9M	0.63%	29
2023 Q1	–	Sell	-129,041	Closed	-$6.58M	–	37
2022 Q4	$6.58M	Hold	129,041	–	–	0.99%	28
2022 Q3	$10.6M	Hold	129,041	–	–	1.7%	19
2022 Q2	$8.73M	Sell	129,041 -108,362	-46%	-$9.94M	1.85%	17
2022 Q1	$26.2M	Buy	+237,403	New	+$29.6M	5.86%	7

Other funds holding KPTI

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Commodore Capital's KPTI Position: Q1 2026 in Review

Commodore Capital opened a new position in Karyopharm Therapeutics (KPTI) in Q1 2026: 1,950,000 shares worth $10.9M. The stake represents 0.63% of the portfolio and ranks #29 among its holdings. This is a return to the name: Commodore Capital previously reported a position in KPTI as recently as Q4 2022.

Commodore Capital first reported a position in KPTI in Q1 2022 and has held it in 5 quarters since. The position peaked at $26.2M in Q1 2022. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

Commodore Capital held 1,950,000 shares of Karyopharm Therapeutics worth $10.9M as of Q1 2026.
Karyopharm Therapeutics was a new Commodore Capital position in Q1 2026.
Karyopharm Therapeutics made up 0.63% of Commodore Capital's portfolio in Q1 2026, its #29 holding.
Commodore Capital first reported a position in Karyopharm Therapeutics in Q1 2022 and has held it in 5 quarters since.
Commodore Capital's Karyopharm Therapeutics position peaked at $26.2M in Q1 2022.
77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Commodore Capital's 13F filing for Q1 2026, filed 15 May 2026.